Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an associate professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high risk, advanced and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).  He is also involved in the development of new radioligand therapeutics.

His research program has four aims: 1) To develop a dynamic imaging method based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow predicting the patient’s response to antiandrogen treatments. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to identify the very high risk prostate cancer and to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells.  4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
152 entries « 15 of 16 »

Shuch B, Pantuck AJ, Pouliot F, Finley DS, Said JW, Belldegrun AS, Saigal C

Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance

Journal Article

BJU Int, 108 (3), 2011.

Abstract | Links:

Shuch B, Crispen PL, Leibovich BC, Larochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML

Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?

Journal Article

BJU Int, 107 (5), 2011.

Abstract | Links:

Finley DS, Pouliot F, Chin AI, Shuch B, Pantuck AJ, Belldegrun AS, Dekernion JB

Immunological therapy in urological malignancy: novel combination strategies

Journal Article

Int J Urol, 18 (2), 2011.

Abstract | Links:

Finley DS, Pouliot F, Miller DC, Belldegrun AS

Primary and salvage cryotherapy for prostate cancer

Journal Article

Urol Clin North Am, 37 (1), 2010.

Abstract | Links:

Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS

Contemporary management of renal tumors with venous tumor thrombus

Journal Article

J Urol, 184 (3), 2010.

Abstract | Links:

Pouliot F, Wu L

Cardiac glycosides may affect prostate specific antigen levels

Journal Article

J Urol, 184 (5), 2010.

| Links:

Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ

Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy

Journal Article

Cancer, 116 (3), 2010.

Abstract | Links:

Pouliot F, Lebel MH, Audet JF, Dujardin T

Determination of success by objective scintigraphic criteria after laparoscopic pyeloplasty

Journal Article

J Endourol, 24 (2), 2010.

Abstract | Links:

Caumartin Y, Pouliot F, Sabbagh R, Dujardin T

Chylous ascites as a complication of laparoscopic donor nephrectomy

Journal Article

Transpl Int, 18 (12), 2005.

Abstract | Links:

Pouliot F, Labrie C

Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens

Journal Article

Int J Cancer, 81 (1), 1999.

Abstract | Links:

152 entries « 15 of 16 »
Signaler des ajouts ou des modifications

Active projects

  • 3TMPO (Triple-Tracer strategy against Metastatic PrOstate cancer), from 2018-03-07 to 2024-03-31
  • Four-Timepoint Multi-tracer PET imaging to characterize metastatic PrOstate Cancer heterogeneity impact on treatment resistance in subjects beginning a new line of therapy, from 2023-03-31 to 2025-03-31
  • Surveillance of Complex Renal Cysts: The SOCRATIC study, from 2019-10-01 to 2028-09-30
  • Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice, from 2022-04-01 to 2027-03-31
  • Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities, from 2022-10-01 to 2027-09-30

Recently finished projects

  • A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease , from 2021-04-01 to 2022-03-31
  • Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes, from 2022-07-01 to 2023-12-15
  • Imagerie moléculaire relié au cancer de la prostate, from 2023-02-01 to 2024-01-31
  • National Program on Radioligand Therapy for Prostate Cancer, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée, from 2018-04-01 to 2023-06-30
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, from 2019-07-01 to 2023-06-30
Data provided by the Université Laval research projects registery